Gene therapy for primary immunodeficiencies: looking ahead, toward gene correction

Area of Science:

• Biotechnology
• Genetics
• Immunology

Background:

• Allogeneic hematopoietic stem cell transplantation is the standard treatment for severe primary immunodeficiencies (PIDs).
• Gene therapy presents a viable alternative for PIDs patients lacking an HLA-identical donor.
• Viral vector-based gene therapy has shown potential but carries risks like insertional mutagenesis.

Purpose of the Study:

• To explore novel gene therapy strategies for treating severe primary immunodeficiencies (PIDs).
• To address safety concerns associated with previous gene therapy approaches for PIDs.
• To evaluate advanced gene-editing technologies for potential therapeutic applications.

Main Methods:

• Investigating gene correction via DNA double-strand breaks at the endogenous locus.
• Utilizing targeted endonucleases like homing endonucleases and zinc finger nucleases to induce site-specific DNA double-strand breaks.
• Exploring transposon-based systems for site-specific gene insertion into safe genomic locations.

Main Results:

• Gene correction and gene insertion into safe harbors are facilitated by site-specific DNA double-strand breaks.
• Homing endonucleases and zinc finger nucleases enable targeted gene modification.
• Transposons offer an alternative mechanism for site-specific gene integration.

Conclusions:

• Novel gene-editing tools, including nucleases and transposons, show potential for safer and more efficient gene therapy in PIDs.
• These advanced technologies may overcome limitations of viral vector-based approaches.
• Further development of these tools could revolutionize treatment for PIDs and other genetic disorders.